Company / Free Cash Flow
Spyre Therapeutics, Inc. Free Cash Flow History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$157.4M
FY2024
5-year range
-$157.4M / -$54.3M
FY2020-FY2024
Trend
-57.6%
vs FY2023
Sector context
#133 of 194
Health Care
What the data says
At -$157M, Spyre Therapeutics, Inc.'s free cash flow ranks #133 of 194 in the Health Care sector. Free Cash Flow has declined for 6 consecutive years, from -$19M in FY2018 to -$157M in FY2024.
Based on SEC 10-K filings.
-$157M in FY2024.
Declined from -$80M to -$157M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#133 of 194 in Health CareTop 69% of 194This company -$157.4M Sector average $470.6M
▼
-133.5% below sector average
Key checks
Key Insights
- Spyre Therapeutics, Inc.'s free cash flow has declined for 6 consecutive years.
- In FY2024, free cash flow decreased 57.6% year-over-year.
- Ranks #133 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.40 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | -$157.4M | -57.6% |
| FY2023 | -$99.9M | -24.8% |
| FY2022 | -$80.1M | -47.5% |
| FY2021 | -$54.3M | -66.5% |
| FY2020 | -$32.6M | -29.3% |
| FY2019 | -$25.2M | -32.4% |
| FY2018 | -$19.1M | +24.5% |
| FY2017 | -$25.2M | -32.4% |
| FY2016 | -$19.1M | -70.3% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026